Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Resmed Inc (NY: RMD )

241.56 -2.84 (-1.16%)
Streaming Delayed Price Updated: 11:45 AM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Resmed Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Elliott Wave Technical Forecast: Unlocking ASX Trading Success: ResMed Inc
The analysis aims to provide readers with insights into the current market trends and how to capitalize on them effectively. 
Via Talk Markets
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA 
From ResMed Inc.
Via GlobeNewswire
Stryker Stock Sees RS Rating Treks Higher To 71
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
$100 Invested In ResMed 20 Years Ago Would Be Worth This Much Today
Via Benzinga
(RMD) - Analyzing ResMed's Short Interest
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
(RMD) - Analyzing ResMed's Short Interest
Via Benzinga
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
From ResMed Inc.
Via GlobeNewswire
Betting on Nvidia: 3 ETFs to Own for Exposure to the AI Giant
Explore three ETFs with Nvidia exposure to capitalize on the future of AI without having to pick a single winner. 
Via InvestorPlace
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
From ResMed Inc.
Via GlobeNewswire
Why ResMed Stock Is Soaring Today
Investors liked the healthcare technology company's latest quarterly update. 
Via The Motley Fool
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
The alliance with Health Gorilla will provide MatrixCare customers with more than 220 million patient records to streamline workflows and improve patient outcomes. 
From MatrixCare
Via GlobeNewswire
All-Time Highs In Sight: The Critical Signals You Can't Ignore
Is the S&P 500 showing signs of a sustainable rally, or are we headed for a pullback? 
Via Talk Markets
Topics Stocks
Exposures US Equities
ResMed Announces Participation in the RBCCM Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
Top Research Reports For Apple, Linde & Comcast
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Linde plc (LIN) and Comcast Corporation (CMCSA​​​​​​​). 
Via Talk Markets
Inspire Medical Systems Stock Sees IBD RS Rating Rise To 78
On Tuesday, Inspire Medical Systems stock earned an upgrade to its Relative Strength (RS) Rating, from 69 to 78. 
Via Investor's Business Daily
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
Via Benzinga
ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes
ResMed is the biggest maker of CPAPs in the U.S., and says the growing popularity of weight-loss drugs could help diagnosis rates. 
Via Investor's Business Daily
ResMed Analysts Boost Their Forecasts After Better-Than-Expected Earnings
Via Benzinga
Why Alphabet Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday. 
Via Benzinga
Topics Economy
Exposures Interest Rates
RMD Stock Earnings: ResMed Beats EPS, Beats Revenue for Q3 2024
RMD stock results show that ResMed beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use. 
Via Investor's Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals. 
Via The Motley Fool
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
The results also pressured ResMed, a maker of CPAPs. CPAPs are the common treatment for sleep apnea. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
Via Benzinga
Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Uber Technologies, Inc. (NYSE: UBER). 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.